ISIS 304801

03/30/2018 - "Herein, this paper will review recent advance in pathophysiology of diabetic dyslipidemia and the role of ApoCIII in this condition, with focus on describing a novel drug volanesorsen as potential treatment strategy."
03/30/2018 - "Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen."
03/30/2018 - "Recently, volanesorsen as a promising ApoIII inhibitor was shown to improve the lipid profile in patients with diabetic dyslipidemia. "
08/01/2016 - "Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes."
11/09/2017 - "Evidence is now emerging that volanesorsen, a second-generation antisense oligonucleotide drug targeting ApoCIII messenger RNA resulting in decreases in TG in patients with familial chylomicronemia syndrome, severe hypertriglyceridemia, and metabolic dyslipidemia with type 2 diabetes giving support to the hypothesis that ApoCIII is a powerful inhibitor of LPL, and when reduced, endogenous clearance of TRLs can result in substantial reductions in TG levels. "

01/01/2019 - "We conducted a phase 3, double-blind, randomized 52-week trial to evaluate the safety and effectiveness of volanesorsen in 66 patients with familial chylomicronemia syndrome. "
07/01/2018 - "The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study."
10/22/2021 - "Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report."
08/01/2021 - "Volanesorsen for treatment of familial chylomicronemia syndrome."
12/01/2018 - "Volanesorsen for treatment of patients with familial chylomicronemia syndrome."

11/01/2023 - "Otherwise, at this time, the side effects of volanesorsen may be too severe to justify its use for mild episodes of FCS or hypertriglyceridemia."
05/01/2023 - "APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia."
02/13/2022 - "Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia."
01/01/2018 - "In this narrative review, we present the currently available clinical evidence on the efficacy and safety of volanesorsen for the treatment of hypertriglyceridemia."
11/01/2017 - "In this narrative review we present the currently available clinical evidence on the efficacy and safety of volanesorsen for the treatment of hypertriglyceridemia."

04/01/2022 - "However, approval of and access to volanesorsen are restricted since a substantial proportion of treated FCS patients developed thrombocytopenia. "
10/01/2020 - "Some safety concerns have been raised with the use of volanesorsen, mainly represented by the occurrence of thrombocytopenia. "
02/13/2022 - "The main side effect of volanesorsen therapy is thrombocytopenia, which should be monitored and treated accordingly. "
12/26/2019 - "Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia. "
12/26/2019 - "Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia."

08/01/2016 - "Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes."
11/09/2017 - "Evidence is now emerging that volanesorsen, a second-generation antisense oligonucleotide drug targeting ApoCIII messenger RNA resulting in decreases in TG in patients with familial chylomicronemia syndrome, severe hypertriglyceridemia, and metabolic dyslipidemia with type 2 diabetes giving support to the hypothesis that ApoCIII is a powerful inhibitor of LPL, and when reduced, endogenous clearance of TRLs can result in substantial reductions in TG levels. "
08/01/2016 - "To determine the effects of volanesorsen (ISIS 304801), a second-generation 2'-O-methoxyethyl chimeric antisense inhibitor of apolipoprotein (apo)C-III, on triglyceride (TG) levels and insulin resistance in patients with type 2 diabetes. "